Li_2024_Eur.J.Med.Chem_284_117198

Galantamine plays a crucial role in the management of brain disorders. In this study, a series of galantamine analogues were designed, synthesized and evaluated as potential therapeutic agents for Alzheimer's disease (AD). Compound C2, a dual inhibitor of cholinesterase, was obtained by introducing a benzylpyridine ring to the hydroxyl group of galantamine. Compared to galantamine (hAChE, IC(50) = 1529 +/- 6 nM), C2 exhibited excellent inhibitory activities against hAChE (IC(50) = 513.90 +/- 9.60 nM) and hBuChE (IC(50) = 357.77 +/- 10.24 nM). Further studies revealed that C2 possessed significant abilities to protect PC12 cells from H(2)O(2)-induced apoptosis and reactive oxygen species (ROS) production. The acute toxicity test in vivo indicated that C2 exhibited a remarkable safety profile. Whether in the acute memory impairment induced by the Abeta(1-42) model or in the amnesia induced by the scopolamine model, oral administration of C2 demonstrated superior improvement on cognition and spatial memory. In summary, both in vitro and in vivo results suggest that C2 deserves to be further explored as an anti-AD agent.